Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zai Lab Ltd ADR
(NQ:
ZLAB
)
24.86
+0.72 (+2.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Ltd ADR
< Previous
1
2
3
4
Next >
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
September 17, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
August 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in September Investor Conferences
August 22, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Investor Alert: Investigation over Potential Wrongdoing
November 15, 2023
San Diego, CA -- (SBWIRE) -- 11/15/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited.
Via
SBWire
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
August 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
July 16, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
July 15, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
July 10, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
June 11, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 22, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
May 20, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in May and June Investor Conferences
May 16, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
May 14, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
May 12, 2024
From
Zai Lab Limited
Via
Business Wire
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
May 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
May 08, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
April 15, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
April 11, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
April 02, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
April 01, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
March 13, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in March Investor Conference
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
February 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
January 25, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
January 10, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in January Investor Conference
December 19, 2023
From
Zai Lab Limited
Via
Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
December 13, 2023
From
Paratek Pharmaceuticals, Inc.
Via
GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
December 12, 2023
From
Zai Lab Limited
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.